Transplant Registry Unified Management Program
Trump Administration and Pfizer Strike ‘Most Favored Nation’ Drug Price Deal
Trump; Pfizer; most favored nation; drug prices; Medicaid; TrumpRx; direct-to-consumer; pharmaceutical industry; PhRMA; AmericasMedicines.com
Trump Administration Pauses Pharmaceutical Tariffs to Negotiate Industry Agreements
Trump; pharmaceutical tariffs; tariff pause; drug pricing; domestic manufacturing; Section 232 investigation; branded drugs; patented drugs
Trump Administration Teases MFN Drug Pricing Rule as Commitment Deadline Looms for Companies
Trump administration; Most-Favored-Nation (MFN) pricing; drug pricing; executive order; pharmaceutical manufacturers; Medicaid; direct-to-consumer sales; price parity; commitment deadline; tariffs; international reference price
Trump Administration Launches Tariff Probe into Medtech and Pharmaceutical Industries
Trump administration; tariffs; medtech industry; pharmaceutical imports; Section 232 investigation; semiconductor tariffs; national security; supply chain; manufacturing; medical devices
Trump Administration Weighs Severe Restrictions on US Pharmas Licensing Chinese Medicines
Trump administration; Chinese medicines; executive order; pharmaceutical industry; licensing restrictions; national security; lobbying; Pfizer; AstraZeneca; biotech; drug manufacturing; FDA review
Japan Wins Exemption for Generics in US-Japan Trade Deal
Japan; US Trade Deal; generic pharmaceuticals; tariff exemption; semiconductor supply chains; Trump administration
Trump’s Most Favored Nation Policy and EU Generics: Recent Developments
Trump; Most Favored Nation policy; EU generics; drug pricing; tariffs; pharma
US to Stockpile Critical Drug Ingredients Under Latest Trump Executive Order
Trump; Executive Order; drug ingredients; pharmaceutical supply chain; Strategic Active Pharmaceutical Ingredients Reserve; ASPR; domestic manufacturing; national security; essential medicines
Trump Announces Massive Pharma Tariffs Up to 250%, Signals Enforcement Within Days
Trump; pharma tariffs; tariff increase; biopharma; Canada; Section 301; international trade; fentanyl crisis